The role of cyclin-dependent kinase 5 in neuropathic pain.

Kimberly Gomez, Tissiana G M Vallecillo, Aubin Moutal, Samantha Perez-Miller, Rodolfo Delgado-Lezama, Ricardo Felix, Rajesh Khanna

Journal: Pain 2021;161(12):2674-2689

PMID: 32773603

Abstract

The chronification of pain can be attributed to changes in membrane receptors and channels underlying neuronal plasticity and signal transduction largely within nociceptive neurons that initiate and maintain pathological pain states. These proteins are subject to dynamic modification by posttranslational modifications, creating a code that controls protein function in time and space. Phosphorylation is an important posttranslational modification that affects ∼30% of proteins in vivo. Increased phosphorylation of various nociceptive ion channels and of their modulators underlies sensitization of different pain states. Cyclin-dependent kinases are proline-directed serine/threonine kinases that impact various biological and cellular systems. Cyclin-dependent kinase 5 (Cdk5), one member of this kinase family, and its activators p35 and p39 are expressed in spinal nerves, dorsal root ganglia, and the dorsal horn of the spinal cord. In neuropathic pain conditions, expression and/or activity of Cdk5 is increased, implicating Cdk5 in nociception. Experimental evidence suggests that Cdk5 is regulated through its own phosphorylation, through increasing p35's interaction with Cdk5, and through cleavage of p35 into p25. This narrative review discusses the molecular mechanisms of Cdk5-mediated regulation of target proteins involved in neuropathic pain. We focus on Cdk5 substrates that have been linked to nociceptive pathways, including channels (eg, transient receptor potential cation channel and voltage-gated calcium channel), proteins involved in neurotransmitter release (eg, synaptophysin and collapsin response mediator protein 2), and receptors (eg, glutamate, purinergic, and opioid). By altering the phosphoregulatory "set point" of proteins involved in pain signaling, Cdk5 thus appears to be an attractive target for treating neuropathic pain conditions.

Address: Department of Pharmacology, College of Medicine, The University of Arizona, Tucson, AZ, United States.; Department of Physiology, Biophysics and Neuroscience, Center for Research and Advanced Studies (Cinvestav), Mexico City, Mexico.; Department of Cell Biology, Cinvestav, Mexico City, Mexico.; Department of Anesthesiology, College of Medicine, The University of Arizona, Tucson, AZ, United States.; BIO5 Institute, University of Arizona, Tucson, AZ, United States.; Center for Innovation in Brain Sciences, University of Arizona, Tucson, AZ, United States.; Regulonix Holding, Inc, Tucson, AZ, United States.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.